Avego BioScience Capital β Full Portfolio
38 tracked investments Β· listed companies and verified rows first
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)inMartin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)inRobert Weisskoff(Director)in
Co-investorsAliment CapitalF-Prime CapitalIA Seed VenturesMission Bay CapitalMission BiocapitalPontifax AgTech+2 more
Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
BiotechHealthtechAbingdon, Oxfordshire
Brian Di Donato(Chief Financial Officer)David Berman(Head of Research and Development)inTina St. Leger(Chief Human Resources Officer)inBahija Jallal(Chief Executive Officer)inRobert Perez(Director)Peter Ratcliffe(Director)
Co-investorsJDRF T1D Fund
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Co-investorsTSVCAbingworthIkarian Capital
MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.
BiotechRedwood City, US
Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)inJames Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)in
Co-investorsForbionNovo Holdings
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more
Alto Pharmacy is a full-service pharmacy that offers patients medication delivery, cost transparency, and pharmacist access.
ConsumerDigital HealthHealthtechSan Francisco, US
James Karraker(Executive Officer, Director)Mattieu Gamache-Asselin(Founder & CEO)inNichola Eliovits(Director)inNathaniel Kan(Director)Robert Spinner(Director)
Co-investorsBantam GroupCalm VenturesCSC UpshotEvolution VC PartnersFlucas VenturesFOG Ventures+9 more
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Co-investorsAndera PartnersGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life SciencesAgent Capital+2 more
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalPontifax Venture CapitalAmzak HealthDelos CapitalDomain Associates+8 more
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsHealthCapAgent CapitalBiotechnology Value FundCowen Healthcare InvestmentsJohnson & Johnson Innovation β JJDCNorthpond Ventures
Xcelthera develops cell therapy platform technology, serving the biotech and therapeutic development sector.
BiotechDeep TechHardwareHealthtechMedical Devices
Brian Feth(Chief Executive Officer)inJames Lim(Chief Scientific Officer)inShannon Eaker(Chief Technology Officer)in
Co-investorsDynamk Capital
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.
BiotechHealthtechMedical Devices
Azim Surani(Co-founder)
Co-investorsFuture Planet CapitalRA CapitalBrightEdgeForbionVenrock
Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule Ξ±4Ξ²7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD).
BiotechHealthtechMorris Plains, US
Neena Bitritto-Garg(Founder)inGerhard Hagn(Chief Executive Officer)inDanielle Fry(Chief Operating Officer and Chief Legal Officer)inTory Trippe(Vice President, Head of Finance and Corporate Development)inMatthew R. Warr(Senior Vice President, Research & Head of Biology)inAndy Whitney(Chief Scientific Officer)in
Co-investorsGlobal BioAccess Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapitalTaiho Ventures, LLC+4 more
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(Executive Officer, Director)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Co-investorsAndera PartnersB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth VenturesLongwood Fund+3 more
.jpeg){kind=logo}
HealthOutlook applies life sciences and machine learning methods to predict health outcomes.
AI & Machine LearningBiotechDigital Health
MapLight develops neurological and neuropsychiatric drug therapies using a discovery platform that identifies neural circuits linked to disease for targeted treatment of conditions like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.
AI & Machine LearningBiotechHealthtechMedical Devices
Christopher Kroeger, M.D.(Chief Executive Officer, Founder, Board Member)Karl Deisseroth, M.D., Ph.D.(Founder, Scientific Advisory Board)Robert Malenka, M.D., Ph.D.(Founder, Board Member, Scientific Advisory Board)
myTomorrows operates an online platform and patient navigation service that helps patients and their physicians discover and access clinical trials, expanded access programs, and treatments in development.
BiotechDigital HealthHealthtech
Ronald Brus(Founder, MD)in
Co-investorsBalderton Capital
NAV is a privately owned fund administrator, founded in 1991, that provides fund administration services for funds domiciled across numerous global jurisdictions.
Enterprise SoftwareFintechSaaS
Co-investorsHivemind Capital LLCHivemind Capital Partners
PBS Biotech develops Vertical-Wheel bioreactors and related accessories for scalable manufacturing of cell therapies, including allogeneic therapies derived from induced pluripotent stem cells, mesenchymal stem cells, and CAR-T or NK cells.
BiotechHardwareMedical DevicesCamarillo, US
Brian Lee(Executive Officer, Director)inMatt Croughan(Executive Officer)Nelson Bermudez(Executive Officer)inTerrell Mathews(Executive Officer)inBryan Poltilove(Director)Jung Lim(Director)
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsOUP (Osage University Partners)Peregrine VenturesAbbVieNovartis Venture FundThe Column Group
Sebela Pharmaceuticals markets and distributes pharmaceutical products to healthcare providers throughout the United States, with select products also sold internationally through marketing partners.
BiotechFemTechMedical DevicesBraintree, US
Alan Cooke(CEO)in
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+3 more
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsDelos CapitalPfizer Venture InvestmentsAgent Capital
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Alimera SciencesArch Oncology IncAtomVie Global RadiopharmaDigitally-powered pharmacy companyEllie DiagnosticsEyevance PharmaceuticalsHealth prediction company using proteomicsMemento MedicinesSaol TherapeuticsSpecialty pharmaceutical companyT cell receptor biotechnology companyTRexBio
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.